A multi-residue method was developed that allows for the simultaneous determination of psychoactive compounds such as opioids, tranquilizers, antiepileptics (primidone, carbamazepine plus two metabolites),the cocaine metabolite benzoylecgonine, the antidepressant doxepin, as well as the calcium channel blocker verapamil in raw and treated wastewater, surface water, groundwater, and drinking water. After solid-phase extraction with Oasis HLB at neutral pH, the analytes were detected by LC electrospray tandem MS in the positive ion mode. With a few exceptions relative recoveries of the analytes exceeded 70%. The limits of quantification were in the low ng/L range. Matrix effects were compensated by using appropriate deuterated or 13C-15N-labeled surrogate standards. For raw and treated wastewater, concentration factors were lowered to reduce matrix effects. Most analytes (15 of 20) were found in raw and treated wastewater as well as in surface water, and hence, are presumably ubiquitously present in the environment. Antiepileptics, the opium alkaloids morphine and codeine, dihydrocodeine, the two tranquilizers oxazepam and temazepam, the opioid tramadol, doxepin, and verapamil were detected in STP discharges and German rivers at concentrations up to the microg/L range. In drinking water, only carbamazepine, its metabolite 10,11-dihydroxy-10,11-dihydrocarbamazepine, and primidone were present at concentrations up to 0.020 microg/L.

No abstract

No abstract

No abstract

No abstract

An analytical method was developed to analyze eight psychoactive pharmaceuticals--including the antiepileptic carbamazepine, the opiates morphine, codeine, dihydrocodeine, the opiode tramadol, and the tranquilizers diazepam, oxazepam, temazepam--and the antibiotic sulfamethoxazole as well as three metabolites (10,11-dihydrocarbamazepine (DHC), 10,11-dihydroxy-10, 11-dihydrocarbamazepine, and N4-acetylsulfamethoxazole) in river sediments. Relative recoveries of all analytes exceeded 97% using either deuterated or 13C15N-labeled surrogate standards. Sorption isotherms of all analytes were constructed at pH 6.5-6.6 on two natural river sediments (Burgen and Dausenau) that differed in organic carbon contents and particle size distributions. Affinities of all analytes were up to an order of magnitude higher for the Dausenau sediment in comparison to the Burgen sediment. Isotherms were well described by the Freundlich model. Sorption of all analytes was linear on the Burgen sediment except for structurally similar carbamazepine (n = 0.90) and DHC (n = 0.88). Conversely, most analytes showed pronounced nonlinear sorption to the Dausenau sediment (n = 0.77-0.92) except for positively charged codeine, dihydrocodeine, and tramadol. Linear sorption of the latter was taken to arise from concentration-independent electrostatic interactions of the organocations with negatively charged surfaces on clay minerals or in the sediment organic matter. Desorption gave rise to hysteresis in 13 out of 16 investigated analyte-sorbent systems. Hysteresis was likely due to slow desorption kinetics beyond 24 h used in the experiment.

No abstract

The veterinary parasiticide ivermectin was selected as a case study compound within the project ERAPharm (Environmental Risk Assessment of Pharmaceuticals). Based on experimental data generated within ERAPharm and additional literature data, an environmental risk assessment (ERA) was performed mainly according to international and European guidelines. For the environmental compartments surface water, sediment, and dung, a risk was indicated at all levels of the tiered assessment approach. Only for soil was no risk indicated after the lower tier assessment. However, the use of effects data from additional 2-species and multispecies studies resulted in a risk indication for collembolans. Although previously performed ERAs for ivermectin revealed no concern for the aquatic compartment, and transient effects on dung-insect populations were not considered as relevant, the present ERA clearly demonstrates unacceptable risks for all investigated environmental compartments and hence suggests the necessity of reassessing ivermectin-containing products. Based on this case study, several gaps in the existing guidelines for ERA of pharmaceuticals were shown and improvements have been suggested. The action limit at the start of the ERA, for example, is not protective for substances such as ivermectin when used on intensively reared animals. Furthermore, initial predicted environmental concentrations (PECs) of ivermectin in soil were estimated to be lower than refined PECs, indicating that the currently used tiered approach for exposure assessment is not appropriate for substances with potential for accumulation in soil. In addition, guidance is lacking for the assessment of effects at higher tiers of the ERA, e.g., for field studies or a tiered effects assessment in the dung compartment.